Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: A phase II study (P-H482) of the Eastern Cooperative Oncology Group

Peter H. Wiernik*, Leo I. Gordon, Martin M. Oken, Jules E. Harris, Michael J. O'Connell

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Mitoguazone is a unique antitumor agent that interferes with polyamine synthesis that has been reported to have activity against AIDS-related malignant lymphoma. We, therefore, tested this agent for activity against chronic lymphocytic leukemia (CLL) in this phase II study. Mitoguazone, 500 mg/M2 was given intravenously weekly to 13 patients with relapsed or refractory, previously treated Rai stages 2-4 CLL. There were no complete or partial responses as judged by standard criteria. Toxicity was acceptable. Mitoguazone in the dose and schedule employed in this study has no significant activity as a single agent in patients with relapsed or refractory CLL.

Original languageEnglish (US)
Pages (from-to)375-377
Number of pages3
JournalLeukemia and Lymphoma
Volume35
Issue number3-4
DOIs
StatePublished - Jan 1 1999

Keywords

  • Chronic lymphocytic leukemia treatment
  • Mitoguazone

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: A phase II study (P-H482) of the Eastern Cooperative Oncology Group'. Together they form a unique fingerprint.

Cite this